As filed with the Securities and Exchange Commission on March 28, 2023

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

NEXIMMUNE, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware		45-2518457
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

 

9119 Gaither Road Gaithersburg, MD		20877
(Address of Principal Executive Offices)		(Zip Code)

2021 Equity Incentive Plan

(Full title of the plans)

Kristi Jones

Chief Executive Officer

NexImmune, Inc.

9119 Gaither Road

Gaithersburg, MD 20877

(301) 825-9810

(Name, address and telephone number, including area code, of agent for service)

 

 

Copies to:

 

John T. Rudy, Esq. Matthew T. Simpson, Esq. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. One Financial Center Boston, MA 02111 (617) 542-6000		John Trainer Chief Financial Officer NexImmune 9119 Gaither Road Gaithersburg, MD 20877 (301) 825-9810

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer		☐		Accelerated filer		☐
Non-accelerated filer		☒		Smaller reporting company		☒
				Emerging Growth Company		☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

 

 

 

EXPLANATORY NOTE

This Registration Statement registers 1,303,923 additional shares of common stock, par value $0.0001 per share (“Common Stock”), of NexImmune, Inc. (the “Registrant”) under the Registrant’s 2021 Equity Incentive Plan (the “Plan”), representing an increase of 1,303,923 shares of Common Stock reserved for issuance under the Plan, effective January 1, 2023 by operation of the “evergreen” provision contained in the Plan. This Registration Statement registers additional securities of the same class as other securities for which a registration statement filed on Form S-8 of the Registrant relating to one or more employee benefit plans is effective (File No.  333-253527). The information contained in the Registrant’s registration statement on Form S-8 (File No. 333-253527) is hereby incorporated by reference pursuant to General Instruction E of Form S-8.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 8.

Exhibits.

 

Exhibit Number

Exhibit Description

Incorporated by Reference herein from Form or Schedule

Filing Date

SEC File/ Reg. Number

4.1

Form of Common Stock Certificate of the Registrant

Form S-1 (Exhibit 4.1)

02/8/2021

333-252220

4.2

Sixth Amended and Restated Certificate of Incorporation of the Registrant

Form 8-K (Exhibit 3.1)

02/18/2021

001-40045

4.3

Amended and Restated Bylaws of the Registrant

Form 8-K (Exhibit 3.2)

02/18/2021

001-40045

5.1*

Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. as to the legality of the securities being registered

23.1*

Consent of Ernst & Young LLP

23.2*

Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1)

24.1*

Powers of Attorney (included on signature page to this Registration Statement)

99.1

NexImmune 2021 Equity Incentive Plan and forms of award agreements thereunder

Form S-1 (Exhibits 10.4.1 and  10.4.2 )

02/08/2021

333-252220

107*

Calculation of Filing Fee

 

*	Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Gaithersburg, Maryland on the 28^th day of March, 2023.

 

SIGNATURES AND POWER OF ATTORNEY

KNOW ALL BY THESE PRESENTS, that each of the directors and officers of NexImmune, Inc. whose signature appears below hereby severally constitutes and appoints Kristi Jones and John Trainer, and each of them singly, his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them singly, for him and in his name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of NexImmune, Inc., and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them or their substitute may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature		Title		Date
/s/ Kristi Jones Kristi Jones, R.P.H.		President, Chief Executive Officer and Director (principal executive officer)		March 28, 2023
/s/ John Trainer John Trainer, M.B.A.		Chief Financial Officer (principal accounting officer and principal financial officer)		March 28, 2023
/s/ Sol J. Barer Sol J. Barer, Ph.D.		Chairman of the Board of Directors		March 28, 2023
/s/ Alan S. Roemer Alan S. Roemer, M.B.A., M.P.H		Director		March 28, 2023
/s/ Tim Bertram Tim Bertram, Ph.D.		Director		March 28, 2023
/s/ Paul D’Angio Paul D’Angio, R.P.H., M.S.J.		Director		March 28, 2023
/s/ Zhengbin (Bing) Yao Zhengbin (Bing) Yao, Ph.D.		Director		March 28, 2023

/s/ Grant Verstandig Grant Verstandig		Director		March 28, 2023
/s/ Leena Gandhi Leena Gandhi, M.D., Ph.D.		Director		March 28, 2023